|
1
|
Kohler BA, Ward E, McCarthy BJ, Schymura
MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA and Edwards
BK: Annual report to the nation on the status of cancer, 1975–2007,
featuring tumors of the brain and other nervous system. J Natl
Cancer Inst. 103:714–736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morton LM, Wang SS, Devesa SS, Hartge P,
Weisenburger DD and Linet MS: Lymphoma incidence patterns by WHO
subtype in the United States, 1992–2001. Blood. 107:265–276. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Friedberg JW: Relapsed/refractory diffuse
large B-cell lymphoma. Hematology Am Soc Hematol Educ Program.
2011:498–505. 2011.PubMed/NCBI
|
|
4
|
Kewalramani T, Zelenetz AD, Nimer SD,
Portlock C, Straus D, Noy A, O'Connor O, Filippa DA,
Teruya-Feldstein J, Gencarelli A, et al: Rituximab and ICE as
second-line therapy before autologous stem cell transplantation for
relapsed or primary refractory diffuse large B-cell lymphoma.
Blood. 103:3684–3688. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mey UJ, Orlopp KS, Flieger D, Strehl JW,
Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, et
al: Dexamethasone, high-dose cytarabine, and cisplatin in
combination with rituximab as salvage treatment for patients with
relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer
Invest. 24:593–600. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Crump M, Baetz T, Couban S, Belch A,
Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, et
al: Gemcitabine, dexamethasone, and cisplatin in patients with
recurrent or refractory aggressive histology B-cell non-Hodgkin
lymphoma: A Phase II study by the National Cancer Institute of
Canada Clinical Trials Group (NCIC-CTG). Cancer. 101:1835–1842.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Velasquez WS, McLaughlin P, Tucker S,
Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E and
Cabanillas F: ESHAP-an effective chemotherapy regimen in refractory
and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol.
12:1169–1176. 1994.PubMed/NCBI
|
|
8
|
López A, Gutiérrez A, Palacios A, Blancas
I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J and
Rodríguez J: GEMOX-R regimen is a highly effective salvage regimen
in patients with refractory/relapsing diffuse large-cell lymphoma:
A phase II study. Eur J Haematol. 80:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thieblemont C and Coiffier B: Lymphoma in
older patients. J Clin Oncol. 25:1916–1923. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Press OW, LeBlanc M, O'Rourke TJ, Gagnet
S, Chapman RA, Balcerzak SP and Fisher RI: Phase II trial of
paclitaxel by 24-hour continuous infusion for relapsed
non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J
Clin Oncol. 16:574–578. 1998.PubMed/NCBI
|
|
11
|
Casasnovas RO, Haioun C, Dumontet C,
Gabarre J, Richard B, Lederlin P, Caillot D, Stamatoullas A, Morel
P, Quesnel B, et al: Phase II study of 3-hour infusion of high dose
paclitaxel in refractory and relapsed aggressive non-Hodgkin's
lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica.
85:502–507. 2000.PubMed/NCBI
|
|
12
|
Kahl BS, Bailey HH, Smith EP, Turman N,
Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J and
Jumonville A: Phase II study of weekly low-dose paclitaxel for
relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin
Oncology Network Study. Cancer Invest. 23:13–18. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Westin JR, McLaughlin P, Romaguera J,
Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L,
Oki Y, et al: Paclitaxel, topotecan and rituximab: Long term
outcomes of an effective salvage programme for relapsed or
refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol.
167:177–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu L, Wang J, Li Y, Zuo L, Zhang Z, Ouyang
J, Fan J and Li H: Development of taxane-containing chemotherapy of
doxorubicin-resistant diffuse large B-cell lymphoma. Anticancer
Drugs. 25:826–831. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Minshall RD, Tiruppathi C, Vogel SM and
Malik AB: Vesicle formation and trafficking in endothelial cells
and regulation of endothelial barrier function. Histochem Cell
Biol. 117:105–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Desai N, Trieu V, Yao Z, Louie L, Ci S,
Yang A, Tao C, De T, Beals B, Dykes D, et al: Increased antitumor
activity, intratumor paclitaxel concentrations, and endothelial
cell transport of cremophor-free, albumin-bound paclitaxel,
ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res.
12:1317–1324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gupta N, Hatoum H and Dy GK: First line
treatment of advanced non-small-cell lung cancer-specific focus on
albumin bound paclitaxel. Int J Nanomedicine. 9:209–221.
2014.PubMed/NCBI
|
|
18
|
Sage H, Johnson C and Bornstein P:
Characterization of a novel serum albumin-binding glycoprotein
secreted by endothelial cells in culture. J Biol Chem.
259:3993–4007. 1984.PubMed/NCBI
|
|
19
|
Tai IT, Dai M, Owen DA and Chen LB:
Genome-wide expression analysis of therapy-resistant tumors reveals
SPARC as a novel target for cancer therapy. J Clin Invest.
115:1492–1502. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sato N, Fukushima N, Maehara N,
Matsubayashi H, Koopmann J, Su GH, Hruban RH and Goggins M:
SPARC/osteonectin is a frequent target for aberrant methylation in
pancreatic adenocarcinoma and a mediator of tumor-stromal
interactions. Oncogene. 22:5021–5030. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suzuki M, Hao C, Takahashi T, Shigematsu
H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T,
Hiroshima K and Gazdar AF: Aberrant methylation of SPARC in human
lung cancers. Br J Cancer. 92:942–948. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mok SC, Chan WY, Wong KK, Muto MG and
Berkowitz RS: SPARC, an extracellular matrix protein with
tumor-suppressing activity in human ovarian epithelial cells.
Oncogene. 12:1895–1901. 1996.PubMed/NCBI
|
|
23
|
Clozel T, Yang S, Elstrom RL, Tam W,
Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B,
Scott DW, et al: Mechanism-based epigenetic chemosensitization
therapy of diffuse large B-cell lymphoma. Cancer Discov.
3:1002–1019. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feugier P, Van Hoof A, Sebban C,
Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E,
Tilly H, Morschhauser F, et al: Long-term results of the R-CHOP
study in the treatment of elderly patients with diffuse large
B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de
l'Adulte. J Clin Oncol. 23:4117–4126. 2005. View Article : Google Scholar : PubMed/NCBI
|
